Peter J. Goadsby, MD PhD DSc FRACP FRCP

Peter J. Goadsby, MD PhD DSc FRACP FRCP

Professor of Neurology, University of California, San Francisco

President of the International Headache Society

Past Editor of Cephalalgia

Professor Goadsby’smajor research interests are in the basic mechanisms of head pain in both experimental settings and in the clinical context of headache. The work of the Headache Group at UCSF involves human imaging and electrophysiological studies in primary headache, as well as experimental studies of trigeminovascular nociception. The aim is to understand what parts of the brain drive and modulate headache syndromes, and how those might be modified by treatment.

Back to List

About Colucid

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures.

Learn More About CoLucid

Lasmiditan

image of lasmiditan structure

Lasmiditan is a member of a novel chemical class called "ditans." Lasmiditan penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway.

Learn More About Lasmiditan